Prenetics Global Limited - Class A Ordinary Share (PRE)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — Apr 2, 2026Investment Snapshot
- P/B of 1.48 — trading near book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -29.1%
- Revenue growing at 41% annually
Prenetics Global Limited - Class A Ordinary Share (PRE) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $254 million . Key value metrics: P/B ratio 1.48, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Prenetics Global Limited - Class A Ordinary Share — Fundamental Analysis Summary
On financial health, PRE shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -29.1% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.25.
StockPik's composite Value Score for PRE is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PRE reports a solid gross margin of 50.3% (sector average: 33.5%) and a negative operating margin of -157.2%.
PRE shows revenue growing at 41% year-over-year, with earnings growing at 23%.